Selecting The Next WHO Director-General: Learning From Predecessors (Part I) - Health Policy Watch
This story deserves to be shared
Send it to someone who'd care, or post it on your networks.
The World Health Assembly chooses a new chief for the World Health Organization in May 2027. Before judging the candidates, assess the predecessors. Eight people have held the post over 78 years. Their varied track record offers pointers for selecting the future incumbent.
Every five years, WHO rediscovers that its Director-Generalship is a political office metaphorically clad in a white coat. The search for Dr Tedros Adhanom Ghebreyesus’s successor is underway: six prospective candidates are publicly listed, others may stay sealed until November. The hopefuls will present their case in webcast member state hearings before the Executive Board shortlists three of them in February 2026. The 80th World Health Assembly makes the final selection by secret ballot next May.
This article is an excerpt. To read the full content, visit the original source. Health Policy Watch
Related articles
Continuous glucose monitors help type 2 diabetes patients spend 5 more hours a day in healthy blood sugar range - Medical Xpress
Continuous glucose monitors (CGMs) could transform diabetes management for millions of Americans with type 2 diabetes who don't take insulin, according to findings published in the New England Journal of Medicine. The clinical trial found that adults using CGMs spent approximately five additional hours each day within their target blood sugar range compared with those receiving routine care. Nearly twice as many CGM users also achieved an A1c level below 7%, a common treatment goal for people with diabetes.
Wearing headphones during surgery may reduce nausea and vomiting afterward - Medical Xpress
Patients who wore noise-canceling headphones during minimally invasive gynecological surgery were significantly less likely to experience postoperative nausea and vomiting (PONV), suggest findings from a randomized clinical trial presented at the Anesthesiology 2026 annual meeting.
Kefah Mokbel: Can Whole-Genome Sequencing-Based ctDNA Monitoring Help Personalize Adjuvant Treatment? - Oncodaily
“Beyond Detecting Cancer Recurrence: Can Whole-Genome Sequencing-Based ctDNA Monitoring Help Personalize Adjuvant Treatment? An exciting new study published in The Oncologist highlights the clinical potential of Signatera Genome, a whole-genome sequencing (WGS)-based, tumor-informed circulating tumor DNA (ctDNA) assay, not only for detecting molecular residual disease (MRD), but also for potentially informing adjuvant treatment decisions.
0 comments
No comments yet. Be the first to share your thoughts!